The thesis
PanicFade v4 bets on a well-documented market reflex: negative headlines get overreacted to, and prices revert toward fundamentals. The entry logic is deliberately narrow — a name must carry sentiment below -0.4 and already be technically oversold (RSI14 under 35, trading below its SMA20) before the strategy sizes into the fear. Exits are symmetric: it takes reversion (RSI14 back above 50 or price reclaiming the SMA20) and hard-stops fresh lows on continued negativity, treating that as a genuine fundamental break rather than noise. The universe is 24 blue-chip large caps across tech, financials, healthcare, staples, and energy — no illiquid names where mean-reversion edges tend to evaporate. The approach is grounded in 2025 sentiment-feedback research (arXiv:2509.11970), which lends it a credible academic spine.
Recent activity
The strategy has been quiet. Five of the last six scheduled runs executed zero trades — the signal is rare by design. The exception was 1 October: a 5-share buy in MCD at $231.79 and a 21-share exit from BAC at $53.60. That BAC sale is instructive — the position was opened on 15 September at $59.86, so this was a ~10% loss, consistent with the hard-stop firing on continued weakness rather than waiting for a reversion that never came. Other recent entries (NKE at $36.10, HD at $299.12, UNH at $370.31) fit the oversold-large-cap mold.
Less comfortably, the live paper book has drifted lower across the window — total equity slipped from $9,922 on 25 September to $9,732 on 2 October, leaving it modestly below its $10,000 notional start. The engine is behaving, but it isn't currently winning.
Backtest and validation
On paper the record is strong: a 37.93% total return over 1,233 days, a 62.88% win rate across 530 trades, and a contained 9.3% max drawdown. The validation work is the real headline — four of four walk-forward folds positive, a probabilistic Sharpe of 0.985, and out-of-sample results that improved through time (fold 4 posted 21.7% at a 2.44 Sharpe). This is not a curve-fit that only shines in-sample.
Strengths and risks
The strengths are rigor and discipline: clean out-of-sample behavior, tight drawdowns, and a liquid universe. But the caveats are real. The headline Sharpe is a pedestrian 0.96 and the backtest CAGR is just 6.79% — respectable, not spectacular. The deflated Sharpe ratio of 0.56 across 27 trials confirms a positive edge survives multiple-testing adjustment, but with less margin than the 0.985 PSR might suggest. Fold 1, spanning the 2022 bear market, barely cleared zero (1.6%, 0.19 Sharpe) — a reminder that fading panic in a sustained downtrend is where this style gets hurt. Turnover near 5,800% means the edge must survive real-world frictions that a paper book understates. Verdict: a thoughtfully built, honestly validated strategy — worth watching, not yet worth celebrating.